GlassScriptPhysician profile
Bryan Alexander Baker
NPI 1164043303
$1,842.33
in general payments reported to CMS, 2019-2025
17 companies · $754 in 2025
The $754 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.57 · 2023: $485 · 2024: $539 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.38 |
| Education | $382.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $533.11 | 2023-2025 | Ensite, Aveir, Optis |
| Abiomed | $231.58 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $196.58 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $169.09 | 2023-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $137.07 | 2024 | Symplicity G3 |
| Amgen INC. | $130.94 | 2024-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.24 | 2023-2025 | Lifevest |
| Biohaven Pharmaceutical Holding Company LTD. | $64.57 | 2022 | |
| Terumo Medical Corporation | $63.33 | 2025 | Angio-Seal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.43 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $33.74 | 2025 | Farxiga, Lokelma |
| Alnylam Pharmaceuticals INC. | $26.52 | 2025 | Onpattro |
| Pfizer INC. | $23.80 | 2025 | |
| Vifor Pharma, INC. | $20.79 | 2024 | Veltassa |
| Cardiva Medical, INC. | $20.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.38 | 2023 | Verquvo |
| Teleflex LLC | $14.67 | 2025 | Supercross |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.